Overview Dividends

(DOC) Healthpeak Properties - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42250P1030

Properties, Care, Facilities, Research, Outpatient

EPS (Earnings per Share)

EPS Growth (3y CAGR): -75.41%
EPS Trend (3y Corr): -31.0%

Last SUE: -4.00σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 25.23%
Revenue Trend (3y Corr): 90.9%

Last SUE: 4.00σ
Qual. Beats: 1

Risk via 10d forecast
Volatility	25.7%
Value at Risk 5%th	40.6%
Relative Tail Risk	-4.11%

Reward TTM
Sharpe Ratio	-0.51
Alpha	-19.65

Character TTM
Hurst Exponent	0.413
Beta	0.502
Beta Downside	0.720

Drawdowns 3y
Max DD	40.71%
Mean DD	19.70%
Median DD	21.38%

Description: DOC Healthpeak Properties October 31, 2025

Healthpeak Properties, Inc. (NYSE: DOC) is a fully integrated REIT and S&P 500 constituent that owns, operates, and develops premium real-estate assets dedicated to healthcare discovery and delivery. Its portfolio is concentrated in life-science labs, medical office buildings, and senior housing, positioning the company within the GICS sub-industry “Health Care REITs.”

Key quantitative highlights (as of the latest FY 2024 filing) include an occupancy rate of roughly 96 % across its life-science and medical-office assets, a FY 2024 adjusted FFO of about $1.12 billion (≈ 6.5 % year-over-year growth), and a dividend yield near 5.8 % paid quarterly. The REIT’s performance is closely tied to macro drivers such as the aging U.S. population (projected to reach 21 % of the total by 2030), sustained federal funding for medical research, and the prevailing interest-rate environment, which influences both borrowing costs and the relative attractiveness of dividend-yielding REITs versus fixed-income alternatives.

If you want a deeper, data-rich analysis of DOC’s valuation metrics and scenario modeling, a quick look at ValueRay’s platform can provide the granular tools needed for further research.

DOC Stock Overview

Market Cap in USD	12,294m
Sub-Industry	Health Care REITs
IPO / Inception	1987-11-05
Return 12m vs S&P 500	-23.0%
Analyst Rating	4.25 of 5

DOC Dividends

Metric	Value
Dividend Yield	6.94%
Yield on Cost 5y	5.82%
Yield CAGR 5y	-12.14%
Payout Consistency	97.1%
Payout Ratio	504.2%

DOC Growth Ratios

Metric	Value
CAGR 3y	-4.17%
CAGR/Max DD Calmar Ratio	-0.10
CAGR/Mean DD Pain Ratio	-0.21
Current Volume	6021.6k
Average Volume	7383.9k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-38.2m TTM) > 0 and > 6% of Revenue (6% = 184.1m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 1.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -4.73% (prev -23.75%; Δ 19.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 1.24b > Net Income -38.2m (YES >=105%, WARN >=100%)

Net Debt (9.34b) to EBITDA (1.64b) ratio: 5.71 <= 3.0 (WARN <= 3.5)

Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (696.4m) change vs 12m ago -0.54% (target <= -2.0% for YES)

Gross Margin 63.56% (prev 60.01%; Δ 3.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 15.52% (prev 12.80%; Δ 2.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.91 (EBITDA TTM 1.64b / Interest Expense TTM 295.0m) >= 6 (WARN >= 3)

Altman Z'' -1.31

(A) -0.01 = (Total Current Assets 981.7m - Total Current Liabilities 1.13b) / Total Assets 19.58b

(B) -0.30 = Retained Earnings (Balance) -5.85b / Total Assets 19.58b

(D) -0.46 = Book Value of Equity -5.17b / Total Liabilities 11.32b

Total Rating: -1.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.61

1. Piotroski 3.50pt = -1.50

2. FCF Yield 5.74% = 2.87

3. FCF Margin 40.45% = 7.50

4. Debt/Equity 1.24 = 1.78

5. Debt/Ebitda 5.71 = -2.50

6. ROIC - WACC (= -1.38)% = -1.72

7. RoE -0.48% = -0.08

8. Rev. Trend 90.85% = 6.81

9. EPS Trend -31.03% = -1.55

What is the price of DOC shares?

As of November 20, 2025, the stock is trading at USD 17.61 with a total of 6,021,594 shares traded.
Over the past week, the price has changed by +0.42%, over one month by -5.38%, over three months by +4.01% and over the past year by -12.54%.

Is DOC a buy, sell or hold?

Healthpeak Properties has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy DOC.

Strong Buy: 10
Buy: 5
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DOC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	20.9	18.5%
Analysts Target Price	20.9	18.5%
ValueRay Target Price	18.1	2.6%

DOC Fundamental Data Overview November 20, 2025

Market Cap USD = 12.29b (12.29b USD * 1.0 USD.USD)
P/E Forward = 71.9424
P/S = 4.3889
P/B = 1.5816
P/EG = 4.0809
Beta = 1.098
Revenue TTM = 3.07b USD
EBIT TTM = 564.7m USD
EBITDA TTM = 1.64b USD
Long Term Debt = 8.76b USD (from longTermDebt, last quarter)
Short Term Debt = 368.1m USD (from shortTermDebt, last quarter)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.34b USD (from netDebt column, last quarter)
Enterprise Value = 21.64b USD (12.29b + Debt 9.43b - CCE 91.0m)
Interest Coverage Ratio = 1.91 (Ebit TTM 564.7m / Interest Expense TTM 295.0m)
FCF Yield = 5.74% (FCF TTM 1.24b / Enterprise Value 21.64b)
FCF Margin = 40.45% (FCF TTM 1.24b / Revenue TTM 3.07b)
Net Margin = -1.25% (Net Income TTM -38.2m / Revenue TTM 3.07b)
Gross Margin = 63.56% ((Revenue TTM 3.07b - Cost of Revenue TTM 1.12b) / Revenue TTM)
Gross Margin QoQ = 70.02% (prev 60.22%)
Tobins Q-Ratio = 1.10 (Enterprise Value 21.64b / Total Assets 19.58b)
Interest Expense / Debt = 0.81% (Interest Expense 76.8m / Debt 9.43b)
Taxrate = 171.3% (out of range, set to none) (264.0m / 154.1m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.87 (Total Current Assets 981.7m / Total Current Liabilities 1.13b)
Debt / Equity = 1.24 (Debt 9.43b / totalStockholderEquity, last quarter 7.60b)
Debt / EBITDA = 5.71 (Net Debt 9.34b / EBITDA 1.64b)
Debt / FCF = 7.53 (Net Debt 9.34b / FCF TTM 1.24b)
Total Stockholder Equity = 8.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.20% (Net Income -38.2m / Total Assets 19.58b)
RoE = -0.48% (Net Income TTM -38.2m / Total Stockholder Equity 8.03b)
RoCE = 3.36% (EBIT 564.7m / Capital Employed (Equity 8.03b + L.T.Debt 8.76b))
RoIC = 3.07% (EBIT 564.7m / (Assets 19.58b - Curr.Liab 1.13b - Cash 91.0m))
WACC = 4.45% (E(12.29b)/V(21.73b) * Re(7.87%) + (debt cost/tax rate unavailable))
Discount Rate = 7.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 12.79%
[DCF Debug] Terminal Value 79.74% ; FCFE base≈1.15b ; Y1≈1.28b ; Y5≈1.67b
Fair Price DCF = 41.82 (DCF Value 29.07b / Shares Outstanding 694.9m; 5y FCF grow 12.72% → 3.0% )
EPS Correlation: -31.03 | EPS CAGR: -75.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: 90.85 | Revenue CAGR: 25.23% | SUE: 4.0 | # QB: 1

Additional Sources for DOC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle